COMPANY

Virtici

HQ: Seattle, WA source · virtici.com ↗ · West Coast

Location: Seattle, WA · source · Oct 15, 2026

Profile checked Oct 10, 2026

49NIH grants

Funding and NIH signals

NIH award NIH awarded $306K (SBIR Phase I 1R43DE036133-01, new, notice Sep 14, 2026); 6 NIH awards totaling $2.43M in the last 12 months. NIH RePORTER 1R43DE036133-01 (Sep 14, 2026)
Evidence (6 events)
- Sep 14, 2026 · NIH RePORTER 1R43DE036133-01
  Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R43DE036133-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 306464; Administering IC: National Institute of Dental and Craniofacial Research; Project title: A Novel Sublingual Vaccine for Preventing andTreating Periodontitis; Organization type: Domestic For-Profits
- Sep 2, 2026 · NIH RePORTER 1R43AI188659-01A1
  Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R43AI188659-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 306500; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Novel Preventative and Treatment for Klebsiella Pneumoniae Infection; Organization type: Domestic For-Profits
- Aug 26, 2026 · NIH RePORTER 1R44AR087173-01
  Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R44AR087173-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 306341; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: A Bioengineered Probiotic for Resetting Immune Function in Rheumatoid Arthritis; Organization type: Domestic For-Profits
- Aug 13, 2026 · NIH RePORTER 1R44AI188778-01A1
  Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R44AI188778-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 300222; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Novel Immune-modulating Probiotic for Treating Rheumatoid Arthritis; Organization type: Domestic For-Profits
- Jul 21, 2026 · NIH RePORTER 5R43DE034614-02
  Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 5R43DE034614-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 308096; Administering IC: National Institute of Dental and Craniofacial Research; Project title: A Novel Anti-infective Therapy for Treating Periodontitis; Organization type: Domestic For-Profits
- Jun 1, 2026 · NIH RePORTER 5R44HL164202-05
  Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 5R44HL164202-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-01; FY total cost (award amount): 903600; Administering IC: National Heart Lung and Blood Institute; Project title: A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 14, 2026 Grant Government grant — SBIR: $306,464 (annual award, as published), announced Sep 14, 2026. Agency: NIH/NIDCR. Source: government award database. source ↗
Sep 2, 2026 Grant Government grant — SBIR: $306,500 (annual award, as published), announced Sep 2, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 26, 2026 Grant Government grant — SBIR: $306,341 (annual award, as published), announced Aug 26, 2026. Agency: NIH/NIAMS. Source: government award database. source ↗
Aug 13, 2026 Grant Government grant — SBIR: $300,222 (annual award, as published), announced Aug 13, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 21, 2026 Grant Government grant — SBIR: $308,096 (annual award, as published), announced Jul 21, 2026. Agency: NIH/NIDCR. Source: government award database. source ↗
Jun 1, 2026 Grant Government grant — SBIR: $903,600 (annual award, as published), announced Jun 1, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Aug 8, 2025 Grant Government grant — SBIR: $309,038 (annual award, as published), announced Aug 8, 2025. Agency: NIH/NIDCR. Source: government award database. source ↗
Aug 6, 2025 Grant Government grant — SBIR: $698,684 (annual award, as published), announced Aug 6, 2025. Agency: NIH/NIDCR. Source: government award database. source ↗
Apr 11, 2025 Grant Government grant — SBIR: $999,989 (annual award, as published), announced Apr 11, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

Funding

Last 2 years.

Sep 14, 2026 Government grant — SBIR: $306,464 (annual award, as published), announced Sep 14, 2026. Agency: NIH/NIDCR. Source: government award database. source ↗
Sep 2, 2026 Government grant — SBIR: $306,500 (annual award, as published), announced Sep 2, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 26, 2026 Government grant — SBIR: $306,341 (annual award, as published), announced Aug 26, 2026. Agency: NIH/NIAMS. Source: government award database. source ↗
Aug 13, 2026 Government grant — SBIR: $300,222 (annual award, as published), announced Aug 13, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 21, 2026 Government grant — SBIR: $308,096 (annual award, as published), announced Jul 21, 2026. Agency: NIH/NIDCR. Source: government award database. source ↗
Jun 1, 2026 Government grant — SBIR: $903,600 (annual award, as published), announced Jun 1, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Aug 8, 2025 Government grant — SBIR: $309,038 (annual award, as published), announced Aug 8, 2025. Agency: NIH/NIDCR. Source: government award database. source ↗
Aug 6, 2025 Government grant — SBIR: $698,684 (annual award, as published), announced Aug 6, 2025. Agency: NIH/NIDCR. Source: government award database. source ↗
Apr 11, 2025 Government grant — SBIR: $999,989 (annual award, as published), announced Apr 11, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

NIH awards 49

Annual award amounts. Total $24.1M.

Sep 19, 2024 NIH award 1R44DE033568-01 FY2024: $923,623 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Peptide for the Oral Treatment and Prevention source ↗
Aug 15, 2024 NIH award 1R43NS139747-01 FY2024: $700,000 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Blood Test for Early Diagnosis of Frontotempor source ↗
Jun 14, 2024 NIH award 4R44HL164202-03 FY2024: $1,049,994 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Bispecific Antibody for the Treatment of Idi source ↗
Mar 22, 2024 NIH award 5R43AI174574-02 FY2024: $306,500 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Sublingual Vaccine to Prevent Neisseria Gonorr source ↗
Aug 2, 2023 NIH award 3R43AG080879-02S1 FY2023: $257,417 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Antibody that Promotes Neuronal Integrity an source ↗
Aug 1, 2023 NIH award 5R43AG080879-02 FY2023: $281,188 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Antibody that Promotes Neuronal Integrity and source ↗
Jul 31, 2023 NIH award 5R43DE032770-02 FY2023: $306,391 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Small Molecule for the Treatment of Periodonti source ↗
Jun 16, 2023 NIH award 5R44AI152646-04 FY2023: $978,755 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel IL-35 Expressing Probiotic Platform for Induci source ↗
Apr 19, 2023 NIH award 1R43AI174574-01A1 FY2023: $306,500 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Sublingual Vaccine to Prevent Neisseria Gono source ↗
Apr 5, 2023 NIH award 3R43AG080879-01S1 FY2023: $215,712 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Antibody that Promotes Neuronal Integrity an source ↗
Mar 28, 2023 NIH award 5R44HL164202-02 FY2023: $306,492 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Bispecific Antibody for the Treatment of Idiop source ↗
Sep 19, 2022 NIH award 1R43AG080879-01 FY2022: $441,280 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Antibody that Promotes Neuronal Integrity and source ↗
Aug 29, 2022 NIH award 1R43DE032770-01A1 FY2022: $306,463 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Small Molecule for the Treatment of Periodon source ↗
Aug 22, 2022 NIH award 3R43AG076091-02S1 FY2022: $73,171 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Multiparameter Blood Test for Early Detection source ↗
Aug 19, 2022 NIH award 5R43AG076091-02 FY2022: $291,961 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Multiparameter Blood Test for Early Detection source ↗
Jul 8, 2022 NIH award 5R44AI152646-03 FY2022: $979,534 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel IL-35 Expressing Probiotic Platform for Induci source ↗
Mar 31, 2022 NIH award 3R43AG076091-01S1 FY2022: $30,488 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Multiparameter Blood Test for Early Detection source ↗
Mar 20, 2022 NIH award 1R44HL164202-01 FY2022: $306,496 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Bispecific Antibody for the Treatment of Idiop source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N93022C00005-0-9999-1 FY2022: $599,582 awarded for that fiscal year; activity N43 (OTHER_NIH); PI FANGER, NEIL; recipient as written: VIRTICI, LLC, Seattle, WA. DEVELOPMENT OF TOLL-L source ↗
Sep 21, 2021 NIH award 1R43AG076091-01 FY2021: $412,462 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Multiparameter Blood Test for Early Detection source ↗
Jul 14, 2021 NIH award 4R44AI152646-02 FY2021: $994,179 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel IL-35 Expressing Probiotic Platform for Induci source ↗
Jan 21, 2021 NIH award 1R43AI157119-01 FY2021: $299,015 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel LIGHT/TL1A Bispecific Antibody for the Treatme source ↗
Jan 11, 2021 NIH award 5R43AI149906-02 FY2021: $281,113 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Probiotic-Based Nanobody Delivery Platform source ↗
Sep 9, 2020 NIH award 5UT2GM130166-03 FY2020: $1,374,707 awarded for that fiscal year; activity UT2 (STTR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. ASCEND, Accelerating Solutions for Commercialization source ↗
Jun 15, 2020 NIH award 5R43AI147773-02 FY2020: $158,832 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Therapeutic Peptide to Treat P. aeruginosa Inf source ↗
Apr 28, 2020 NIH award 1R44AI152646-01 FY2020: $299,996 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel IL-35 Expressing Probiotic Platform for Induci source ↗
Jan 25, 2020 NIH award 1R43AI149906-01 FY2020: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Probiotic-Based Nanobody Delivery Platform source ↗
Aug 27, 2019 NIH award 3UT2GM130166-02S1 FY2019: $250,000 awarded for that fiscal year; activity UT2 (STTR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. ASCEND, Accelerating Solutions for Commercialization source ↗
Aug 26, 2019 NIH award 4UT2GM130166-02 FY2019: $1,455,915 awarded for that fiscal year; activity UT2 (STTR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. ASCEND, Accelerating Solutions for Commercialization source ↗
Jul 10, 2019 NIH award 1R43AI147773-01 FY2019: $299,836 awarded for that fiscal year; activity R43 (SBIR); PI FANGER, NEIL A; recipient as written: VIRTICI, LLC, Seattle, WA. A Novel Therapeutic Peptide to Treat P. aeruginosa Inf source ↗